Avid Radiopharmaceuticals President and CEO Daniel Skovronsky expressed frustration with the CMS draft decision to provide limited coverage of PET beta-amyloid imaging scans for patients with dementia or neurodegenerative disease. "CMS appears to be challenging the value of an adjunctive tool that can assist physicians in making a more informed diagnosis for patients with cognitive impairment. Restricting coverage could hinder a timely and accurate diagnosis," Skovronsky said in a statement. The agency agreed to cover only one scan per patient under certain terms, saying there is "insufficient" evidence of the test's health benefits.
Published in Brief: